Immuno-oncology Clinical Trials Industry Overview
The global immuno-oncology clinical trials market size was estimated at USD 5.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 13.6% from 2021 to 2028. The growth can be attributed to recent developments in immuno-oncology, changes in lifestyle brought on by urbanization predisposing populations to the rise of cancer, and the growing acceptability of targeted therapy.
Besides, clinical trial participation has also become challenging due to difficulties such as transportation issues to trial sites or testing locations. IQVIA and the Cancer Research Institute collaborated to conduct a survey among oncology investigators to assess the impact of COVID-19 on ongoing and future clinical studies. Remote tools were highly ranked for the assessments. Also, during the COVID-19 pandemic, several regional authorities provided prompt and detailed support for virtual tools and models, indicating that regulators regard patient-centric technology and approaches as feasible answers to this global issue.
Gather more insights about the market drivers, restrains and growth of the Global Immuno-oncology Clinical Trials Market
Immuno-oncology trials account for more than a third of all clinical trials in oncology. Small biotech and specialty pharma are poised to play a critical role in the growth. Immunotherapy advances differ from cytotoxic chemotherapy in the way they work, and these distinctions may have an influence on a dose, response evaluation, biomarker validation, combination therapy selection, and adverse event detection. Understanding and overcoming these barriers will be crucial to the success of immuno-oncology clinical trials and, eventually, market approval.
Treatments focusing on two targets - PD-1/PD-L1 and CTLA-4 - which both negatively control T-cell immune function to promote activation of the body's own immune system - have generated the most significant advances in immuno-oncology. Other than PD-1/PD-L1 and CTLA-4 inhibitors, CAR-T (chimeric antigen receptor T-cell) treatment is another popular immuno-oncology treatment option. CAR-T therapies use a patient's own T-cells, which are extracted, changed to attack cancer, and then put back into the patient's body.
Immuno-oncology (IO) continues to play a significant role in oncology deal-making, accounting for 49% of drug licensing deals and 66% of the total disclosed deal value. 15 of the 21 oncology medication licensing deals worth more than $1 billion were for IO assets, with 9 of those for multi-targeted methods such bispecific antibodies and antibody-drug conjugates. In 2020, the AstraZeneca/Daiichi Sankyo pact was the largest drug licensing deal.
COVID-19 has had a significant impact on cancer and clinical trials, altering therapy and oncology patients in a number of ways. According to the research by Evaluate Vantage, over 170 studies being discontinued as a result of the virus. The pandemic disrupted 920 interventional oncology trials between February and May 2020.
Browse through Grand View Research's Medical Devices Industry Research Reports.
- Hyaluronic Acid Market: The global hyaluronic acid market size was valued at USD 8.9 billion in 2021 and is projected to witness a compound annual growth rate (CAGR) of 7.45% over the forecast period.
- Nephrology And Urology Devices Market: The global nephrology and urology devices market size was valued at USD 5.24 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.8% from 2022 to 2030.
Immuno-oncology Clinical Trials Market Segmentation
Grand View Research has segmented the global immuno-oncology clinical trials market based on phase, design, indication, and region:
Immuno-oncology Clinical Trials Phase Outlook (Revenue, USD Million, 2016 - 2028)
- Phase I
- Phase II
- Phase III
- Phase IV
Immuno-oncology Clinical Trials Design Outlook (Revenue, USD Million, 2016 - 2028)
- Interventional trials
- Observational trials
- Expanded access trials
Immuno-oncology Clinical Trials Indication Outlook (Revenue, USD Million, 2016 - 2028)
- Solid tumors
- Hematological cancer
Immuno-oncology Clinical Trials Regional Outlook (Revenue, USD Million, 2016 - 2028)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East Africa
Key Companies profiled:
Some of the prominent players in the immuno-oncology clinical trials market include:
- Medpace
- Novartis
- Exscientia
- Syneous Health
- AstraZeneca
Order a free sample PDF of the Immuno-oncology Clinical Trials Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
